PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS MARKET ANALYSIS

Cardiovascular diseases remain a leading cause of mortality and morbidity worldwide. The development of peptide as therapeutic agent has been avoided by pharmaceutical industry due to its low stability, size, degradation rate, and poor stability. However, recently, resurgence has taken place in developing peptides in therapeutic action. Peptides are short chains of amino acid monomers linked by peptide bond. Peptides are distinguished from proteins on the basis of size. Increasing prevalence of cardiovascular diseases such as cardiac arrest and chest pain and increasing research and development in peptide-based drug therapies is expected to drive the market growth.

Peptide-based Cardiovascular Therapeutics Market-Drivers

Increasing prevalence of cardiovascular diseases globally is expected to drive the peptide-based cardiovascular therapeutics market growth during the forecast period. For instance, according to the World Health Organization 2017 report, around 17.9 million deaths were recorded from cardiovascular diseases worldwide in 2016.

Furthermore, research and development and clinical trials of new peptide-based therapeutics is expected to drive growth of the peptide-based cardiovascular therapeutics market during the forecast period. For instance, according to the National Center for Biotechnology Information’s 2015 report, there is an increasing interest in peptide formation in pharmaceutical research and development (R&D) and around 140 peptide-based therapeutics are being evaluated in clinical trials.

Peptide-based Cardiovascular Therapeutics Market-Restraints

Rapid metabolism of peptide drug is expected to restrain the peptide-based cardiovascular therapeutics market growth during the forecast period. For instance, according to National Center for Biotechnology Information’s 2015 report, natural peptides have poor absorption, distribution, metabolism, and excretion (ADME) properties with rapid clearance, short half-life, low permeability, and low solubility.

Peptide-based Cardiovascular Therapeutics Market-Regional Analysis

On the basis of region, the peptide-based cardiovascular therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the peptide-based cardiovascular therapeutics market over the forecast period, owing to increasing number of approvals for therapeutic peptides. For instance, according to the Drug Discovery Today Journal, in 2015, over 60 therapeutics peptides were approved by the U.S. Food and Drug Administration (FDA) in the U.S.

Asia Pacific is the fastest growing market for peptide-based cardiovascular therapeutics, due to increasing prevalence of cardiovascular diseases in the region. For instance, according to China’s National Center for Cardiovascular Diseases’ report in 2017, the total number of patient suffering from cardiovascular diseases in China was 290 million.

Peptide-based Cardiovascular Therapeutics Market-Competitive Landscape

Key players operating in the peptide-based cardiovascular therapeutics market include, Pfizer Inc., Apotex Holdings, Inc., Fresenius Kabi USA, AstraZeneca, Corden Pharma GmbH, Merck & Co., Inc., Novetide Ltd., and Dr. Reddy’s Laboratories Limited.

Peptide-based Cardiovascular Therapeutics Market-Taxonomy

The peptide-based cardiovascular therapeutics market is segmented on the basis of drug type, distribution channel, and region.

By Drug Type:

• Bivalirudin
• Eptifibatide

 By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa